Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Daiichi Sankyo
Johnson and Johnson
Chubb
Merck
Julphar
Fuji
Baxter
McKinsey
Argus Health

Generated: October 21, 2017

DrugPatentWatch Database Preview

Hydrochlorothiazide; olmesartan medoxomil - Generic Drug Details

« Back to Dashboard

What are the generic sources for hydrochlorothiazide; olmesartan medoxomil and what is the scope of hydrochlorothiazide; olmesartan medoxomil freedom to operate?

Hydrochlorothiazide; olmesartan medoxomil
is the generic ingredient in two branded drugs marketed by Prinston Inc, Torrent Pharms Ltd, Mylan Pharms Inc, Daiichi Sankyo, Teva Pharms Usa, Alembic Pharms Ltd, and Aurobindo Pharma Ltd, and is included in seven NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Hydrochlorothiazide; olmesartan medoxomil has one hundred and one patent family members in twenty-seven countries and twenty-six supplementary protection certificates in eight countries.

There are thirty-one drug master file entries for hydrochlorothiazide; olmesartan medoxomil. Twelve suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: hydrochlorothiazide; olmesartan medoxomil

US Patents:1
Tradenames:2
Applicants:7
NDAs:7
Drug Master File Entries: see list31
Suppliers / Packagers: see list12
Clinical Trials: see list399
Drug Prices:see low prices
DailyMed Link:hydrochlorothiazide; olmesartan medoxomil at DailyMed

Pharmacology for Ingredient: hydrochlorothiazide; olmesartan medoxomil

Tentative approvals for HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

Applicant Application No. Strength Dosage Form
u► Subscribe20MG;12.5MGTABLET;ORAL
u► Subscribe40MG;25MGTABLET;ORAL
u► Subscribe40MG;12.5MGTABLET;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Prinston Inc
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL207804-003Apr 24, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Prinston Inc
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL207804-002Apr 24, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Alembic Pharms Ltd
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL204233-002Apr 24, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Torrent Pharms Ltd
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL206515-003May 3, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL205391-001Apr 24, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL200532-003Apr 24, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL078827-001Oct 26, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL205391-002Apr 24, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Prinston Inc
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL207804-001Apr 24, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL078827-003Oct 26, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: hydrochlorothiazide; olmesartan medoxomil

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo
BENICAR HCT
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL021532-002Jun 5, 2003► Subscribe► Subscribe
Daiichi Sankyo
BENICAR HCT
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL021532-005Jun 5, 2003► Subscribe► Subscribe
Daiichi Sankyo
BENICAR HCT
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL021532-003Jun 5, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: hydrochlorothiazide; olmesartan medoxomil

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,646,171 Angiotensin II antagonist 1-biphenylmethylimidazole compounds and their therapeutic use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: hydrochlorothiazide; olmesartan medoxomil

Country Document Number Estimated Expiration
Israel114996► Subscribe
Iceland3819► Subscribe
Luxembourg91330► Subscribe
JapanH07121918► Subscribe
Czech Republic287764► Subscribe
Canada2097444► Subscribe
Norway2009019► Subscribe
Czech Republic9301050► Subscribe
HungaryT64329► Subscribe
Australia661153► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00095Netherlands► SubscribePRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
/2009Austria► SubscribePRODUCT NAME: KOMBINATION VON OLMESARTAN MEDOXOMIL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH AKZEPTABLEN SALZES, MIT AMLODIPINBESILAT; NAT. REGISTRATION NO/DATE: 1-27894, 1-27895, 1-27896 20081217; FIRST REGISTRATION: NL 100989, 100990, 100991 20080819
0503785/04Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
0133Netherlands► Subscribe300133, 20120221, EXPIRES: 20170220
00133Netherlands► SubscribePRODUCT NAME: OLMESARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN DE CARBOXYGROEP GEKOZEN UIT DE VOLGENDE : EEN ALKYLGROEP 1-4 KOOLSTOFATOMEN, EEN BENZYLGROEP, EEN ALKANOYLOXYALKYLGROEP WAARIN HET ALKANOYLDEEL 1-5; NATL. REGISTRATION NO/DATE: RVG 28785-RVG 28787 20030527; FIRST REGISTRATION: DE 502.02.00.00,502.02.01.00, 502.02.02.00 20020813
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
00486Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216
056Luxembourg► Subscribe91056, EXPIRES: 20170221
00375Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Colorcon
US Army
UBS
Express Scripts
Novartis
Chubb
Federal Trade Commission
Julphar
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot